Dietary interventions may lower the risk of a heart attack or stroke
Table of Contents
Regardless of how many pounds a person loses, studies indicates that weight reduction injections may lower the risk of heart attack or stroke.
Research indicates that reducing abdominal fat is more important for heart health than reducing total weight, which may result in muscle loss.
According to scientists, it is illogical to restrict the use of the appetite suppressant semaglutide to the most seriously obese individuals.
Prof. John Deanfield, the lead author from University College London, stated that abdominal fat poses a greater threat to cardiovascular health than total weight and advocated for a reconsideration of the usage of semaglutide, which is marketed under the names Ozempic for diabetes and Wegovy for obesity. "Its heart-healthy benefits are not directly correlated with weight loss," he stated. Indeed, it is a medication that directly addresses heart disease and other aging-related conditions.
The study looked at 17,604 semaglutide users who were at least 45 years old, overweight, or obese, and came from 41 different countries.
The study looked at 17,604 semaglutide users who were at least 45 years old, overweight, or obese, and came from 41 different countries.
According to a prior investigation, semaglutide reduced the risk of significant adverse cardiac events by 20%. Researchers now claim that the advantage was noticeable irrespective of the amount of weight dropped while taking the medication.
Benefits were comparable for individuals with the highest BMI scores and those with a body mass index of 27, which is the norm for adults in the UK. It is believed that the drug's other effects, such lowering inflammation in the body, may be the cause of the heart benefits.
Prof. Deanfield stated: "It doesn't make sense to limit its use to a specific period of time and for those with the highest BMIs if your goal is to reduce cardiovascular disease."
Benefits were comparable for individuals with the highest BMI scores and those with a body mass index of 27, which is the norm for adults in the UK. It is believed that the drug's other effects, such lowering inflammation in the body, may be the cause of the heart benefits.
Prof. Deanfield stated: "It doesn't make sense to limit its use to a specific period of time and for those with the highest BMIs if your goal is to reduce cardiovascular disease."
Benefits must be balanced with possible drawbacks. Given the wide spectrum of people this medication and others like it potentially treat, side effect investigations become even more crucial.
Over the next three years, the NHS in England is distributing weight loss shots to 240,000 people, beginning with those who need them the most.
Over the next three years, the NHS in England is distributing weight loss shots to 240,000 people, beginning with those who need them the most.
Post a Comment